P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
Proceedings article published in 2019 by
A. Christopoulou,
F. Marmé,
A. Oaknin,
D. Lorusso,
T. Safra,
G. Lindahl,
A. Chudecka-Glaz,
T. Ciuleanu,
Dc Collins,
F. Demirkiran,
I. Lifrenko,
T. Van Gorp 
,
Rl Coleman,
K. Fujiwara,
Am Oza
and other authors.
,
Rl Coleman,
K. Fujiwara,
Am Oza
and other authors.
